文献速递心律失常

非维生素K拮抗剂口服抗凝药与华法林在房颤患者不同体重指数和体重谱中的疗效与安全性:4项随机临床试验的个体患者数据荟萃分析

Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.
PubMed 文献 · Circulation · 2024-01-24

该研究汇总了4项比较NOAC与华法林治疗房颤的随机试验的个体患者数据,共58 464例患者。结果显示,NOACs总体降低卒中/系统性栓塞事件(HRadj 0.80,95%CI 0.73-0.88),且效果在不同BMI间基本一致;NOACs总体降低大出血(HRadj 0.88,95%CI 0.82-0.94),但高BMI患者获益减弱。死亡和净临床结局总体利于NOACs,但在极高BMI/BW患者中不确定性仍存。

要点

  • NOACs降低卒中/系统性栓塞的疗效在不同BMI和体重间基本一致。
  • NOACs降低大出血的获益随BMI升高而减弱(Ptrend=0.003)。
  • 死亡和净临床结局总体利于NOACs,但极高BMI/BW患者数据不确定。

核心结论

  • NOACs相比华法林在房颤患者中降低卒中/SEE的疗效跨BMI和体重谱基本一致。
  • NOACs降低大出血的获益在高BMI或高体重患者中减弱。
  • 死亡和净临床结局总体利于NOACs,但在极高BMI和体重患者中不确定性仍存。

研究设计与样本

  • 研究类型:个体患者数据荟萃分析,数据来源为COMBINE AF项目,汇总4项NOAC与华法林比较的房颤随机试验。
  • 样本量:共58 464例患者,中位BMI 28.3(IQR 25.2-32.2)kg/m2,中位体重81.0(IQR 70.0-94.3)kg。
  • 因BMI<18.5 kg/m2患者较少(n=598),主要分析限于BMI≥18.5 kg/m2者。

主要发现

  • NOACs总体降低卒中/SEE(HRadj 0.80,95%CI 0.73-0.88;P<0.001),跨BMI趋势检验P=0.48。
  • NOACs总体降低大出血(HRadj 0.88,95%CI 0.82-0.94;P<0.001),但高BMI患者获益减弱(Ptrend=0.003)。
  • 净临床结局总体利于NOACs(HRadj 0.91,95%CI 0.87-0.95;P<0.001),但高BMI患者获益减弱(Ptrend=0.001)。
  • 死亡总体利于NOACs(HRadj 0.91,95%CI 0.86-0.97;P=0.003),高BMI患者获益减弱趋势P=0.08。
  • 按体重分析结果与按BMI分析定性相似。

临床怎么用

  • 房颤患者选择NOACs时,高BMI或高体重者仍可获益于卒中预防,但需关注大出血风险可能增加。
  • 对极高BMI或体重的房颤患者,NOACs在死亡和净临床结局方面的优势不确定,需个体化评估。

局限性

  • BMI<18.5 kg/m2患者数量少(n=598),主要分析未纳入。
  • 极高BMI和体重患者的数据有限,相关结局不确定性仍存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain. METHODS: We analyzed data from COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation), which pooled patient-level data from the 4 pivotal randomized trials of NOAC versus warfarin in patients with atrial fibrillation. The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). Each outcome was examined across BMI and BW. Because few patients had a BMI <18.5 kg/m2 (n=598), the primary analyses were restricted to those with a BMI ≥18.5 kg/m2. RESULTS: Among 58 464 patients, the median BMI was 28.3 (interquartile range, 25.2-32.2) kg/m2, and the median BW was 81.0 (interquartile range, 70.0-94.3) kg. The event probability of stroke/SEE was lower at a higher BMI irrespective of treatment, whereas the probability of major bleeding was lower at a higher BMI with warfarin but relatively unchanged across BMI with NOACs. NOACs reduced stroke/SEE overall (adjusted hazard ratio [HRadj], 0.80 [95% CI, 0.73-0.88]; P<0.001), with a generally consistent effect across BMI (Ptrend across HRs, 0.48). NOACs also reduced major bleeding overall (HRadj, 0.88 [95% CI, 0.82-0.94]; P<0.001), but with attenuation of the benefit at a higher BMI (trend test across BMI [Ptrend], 0.003). The overall treatment effects of NOACs versus warfarin for secondary outcomes were consistent across BMI, with the exception of the net clinical outcome and death. While these outcomes were overall reduced with NOACs (net clinical outcome, HRadj, 0.91 [95% CI, 0.87-0.95]; P<0.001; death, HRadj, 0.91 [95% CI, 0.86-0.97]; P=0.003), these benefits were attenuated at higher BMI (Ptrend, 0.001 and 0.08, respectively). All findings were qualitatively similar when analyzed across BW. CONCLUSIONS: The treatment effect of NOACs versus warfarin in atrial fibrillation is generally consistent for stroke/SEE across the spectrum of BMI and BW, whereas the reduction in major bleeding is attenuated in those with higher BMI or BW. Death and the net clinical outcome are overall reduced with NOACs over warfarin, although there remain uncertainties for these outcomes at a very high BMI and BW.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Patel, Braunwald, Steffel, et al. Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Circulation. 2024. PMID: 38264923. doi:10.1161/CIRCULATIONAHA.123.066279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。